PD-1 is an interdisciplinary topic requiring collaboration among researchers from diverse fields due to its central role in immune regulation, its interaction with PD-L1, and its profound impact on cancer immunotherapy, autoimmune diseases, and the advancement of novel immune checkpoint inhibitors.
Explore the following trending articles in Frontiers in Pharmacology and Frontiers in Drug Discovery.
A review article discussing myocarditis induced by anti-PD-1/PD-L1 agents, including its incidence, characteristics, diagnosis, treatment options, and potential underlying mechanisms.
There is limited knowledge about how flavonoids bind to PD-1/PD-L1 at the atomic level. This study used computational methods to predict the binding mode of flavonoids with PD-1 and PD-L1 proteins.
This research article discusses a new type of antibody called QL401, which is designed to help the immune system fight cancer. It targets two specific molecules on the surface of the cancer cells - PD-L1 and CD47.
This research article discusses ASK120067, a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), which showed potent inhibitory effects on EGFR 20ins mutations that are resistant to standard TKIs.
The article discusses a clinical trial conducted to evaluate the safety and pharmacokinetics of SHR6390, a potent inhibitor of the cytochrome P450 3A4 enzyme. It also exhibits anti-tumor activity as a cyclin-dependent kinase 4/6 inhibitor.
This review offers a recent, thorough literature compilation of contemporary research on the development of hybrid compounds based on coumarin-1,2,3-triazoles as potential anticancer leads throughout the previous 10 years.
Read other impactful articles published in Frontiers in Pharmacology and Frontiers in Drug Discovery